Sanibel Captiva Trust Company Inc. Acquires 110 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sanibel Captiva Trust Company Inc. increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 643 shares of the pharmaceutical company’s stock after purchasing an additional 110 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Vertex Pharmaceuticals were worth $259,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Northwest Investment Counselors LLC purchased a new position in shares of Vertex Pharmaceuticals in the third quarter valued at $25,000. Dunhill Financial LLC grew its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares in the last quarter. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at about $27,000. Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth about $33,000. Finally, Truvestments Capital LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $35,000. Institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on VRTX shares. Royal Bank of Canada upped their target price on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Morgan Stanley increased their price objective on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Citigroup started coverage on Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 target price on the stock. Scotiabank raised their price target on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the company a “sector perform” rating in a report on Monday, December 23rd. Finally, Bank of America cut their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a report on Thursday, December 19th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $422.00 on Monday. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The stock has a market capitalization of $108.68 billion, a P/E ratio of -212.06, a P/E/G ratio of 2.11 and a beta of 0.40. The company’s 50-day moving average is $440.94 and its 200 day moving average is $466.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.67 EPS. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.